Insight Molecular Diagnostics Inc.

As of June 30, 2026, Insight Molecular Diagnostics Inc. carries a market capitalization of 185.62M, placing it among publicly traded companies globally. Its enterprise value stands at 170.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Insight Molecular Diagnostics Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Insight Molecular Diagnostics Inc. has 32.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 115.31, and the price-to-book ratio stands at -8.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 102.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 170.49M versus a market cap of 185.62M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Insight Molecular Diagnostics Inc. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.32, indicating conservative leverage, while an interest coverage ratio of -488.32 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -123.46, reflecting losses generated across the asset base. The company generates approximately 29,955.16 in revenue per employee across its workforce of 55.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.92 indicates how many times Insight Molecular Diagnostics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Insight Molecular Diagnostics Inc.'s stock has declined approximately 48.91% over the past 52 weeks. The 50-day moving average sits at 3.86, while the 200-day moving average is 4.68.

Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. generated 1.67M in revenue and converted that into -49.36M in net income, yielding earnings per share of -1.46. EBITDA reached -47.85M, while operating income came in at -37.04M.

As of June 30, 2026, Insight Molecular Diagnostics Inc. holds 17.76M in cash and equivalents against 2.63M in total debt, resulting in a net debt position of -17.76M. Total book value stands at -21.30M, with working capital of 10.26M providing operational flexibility.

Insight Molecular Diagnostics Inc. produced -27.08M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.92M in capital expenditures, free cash flow totaled -31.00M - equivalent to -0.92 per share.

Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. posted a gross margin of 48.32, reflecting its pricing power and cost economics. The operating margin of -2,217.90 and net profit margin of -2,955.63 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.80, meaning Insight Molecular Diagnostics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Insight Molecular Diagnostics Inc.'s most recent stock split took place on July 26, 2023 with a 20:1 split ratio.

As of June 30, 2026, Insight Molecular Diagnostics Inc. has an Altman Z-Score of -21.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.